Last reviewed · How we verify
Exenatide 10microgram
Exenatide 10microgram is a Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved.
At a glance
| Generic name | Exenatide 10microgram |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exenatide 10microgram CI brief — competitive landscape report
- Exenatide 10microgram updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Exenatide 10microgram
What is Exenatide 10microgram?
Exenatide 10microgram is a Small molecule drug developed by GlaxoSmithKline.
Who makes Exenatide 10microgram?
Exenatide 10microgram is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is Exenatide 10microgram in?
Exenatide 10microgram is FDA-approved (marketed).
Related
- Manufacturer: GlaxoSmithKline — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing